Who Exports Diazepam from India — 75 Suppliers Behind a $7.5M Market
India's diazepam export market is supplied by 75 active exporters who collectively shipped $7.5M across 534 shipments. VENOR PHARMA LIMITED leads with a 18.4% market share, followed by MYLAN LABORATORIES LIMITED and GLAND PHARMA LTD. The top 5 suppliers together control 56.4% of total export value, reflecting a moderately competitive market structure.
Top Diazepam Exporters from India — Ranked by Export Value
VENOR PHARMA LIMITED is the leading diazepam exporter from India, holding a 18.4% share of the $7.5M market across 534 shipments from 75 exporters. The top 5 suppliers — VENOR PHARMA LIMITED, MYLAN LABORATORIES LIMITED, GLAND PHARMA LTD, CIRON DRUGS AND PHARMACEUTICALS PRIVATE LIMITED, SWISS PARENTERALS LIMITED — collectively control 56.4% of total export value, indicating a moderately concentrated market. Individual shares are: VENOR PHARMA LIMITED (18.4%), MYLAN LABORATORIES LIMITED (16.8%), GLAND PHARMA LTD (11.1%), CIRON DRUGS AND PHARMACEUTICALS PRIVATE LIMITED (5.2%), SWISS PARENTERALS LIMITED (4.9%).
Top Diazepam Exporters from India
Ranked by export value · 75 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | VENOR PHARMA LIMITED VERZEPAM INJ DIAZEPAM BP 5MG/ML,2ML AMPPHARMACEUTICALS:BRAND. VERZEPAM INJ.DIAZEPAM BP 5MG/ML,BRAND VERZEPAM INJ DIAZEPAM BP 5MG/ML 2M | $1.4M | 28 | 18.4% |
| 2 | MYLAN LABORATORIES LIMITED DIAZEPAM 5MG 500 TABLETS PACKS 29166DIAZEPAM INJ USP 10MG/2ML 10`S AP USDIAZEPAM INJ USP 10MG/2ML 10'S AP US | $1.3M | 1 | 16.8% |
| 3 | GLAND PHARMA LTD DIAZEPAM 5MG 500 TABLETS PACKS 29166DIAZEPAM INJ USP 10MG/2ML 10`S AP USDIAZEPAM INJ USP 10MG/2ML 10'S AP US | $833.6K | 1 | 11.1% |
| 4 | CIRON DRUGS AND PHARMACEUTICALS PRIVATE LIMITED 200000 AMPOULES OF DIAZEPAM INJECTION 5MG/ML 2 ML1,00,000 AMPOULES OF DIAZEPAM 5 MG/ML 2ML 2ML AMPDIAZEPAM INJECTION BP 5 MG/ML, 2ML | $386.6K | 9 | 5.2% |
| 5 | SWISS PARENTERALS LIMITED BSMITH DIAZEPAM INJECTION (DIAZEPAM 10MGJARZEPAM (5DIAZI DIAZEPAM INJECTION 5MG/ML, 2 ML393,600 AMPS | $365.7K | 12 | 4.9% |
| 6 | VERVE HUMAN CARE LABORATORIES BRAND VERZEPAM INJ DIAZEPAM BP 5MG/ML 2MBRAND VERZEPAM INJ DIAZEPAM BP 5MG/ML,2MINJECTION DIAZEPAM INJECTION USP 10MG/2M | $329.8K | 9 | 4.4% |
| 7 | NEON LABORATORIES LIMITED BRAND VERZEPAM INJ DIAZEPAM BP 5MG/ML 2MBRAND VERZEPAM INJ DIAZEPAM BP 5MG/ML,2MLORI,DIAZEPAM INJ.BP 5MG/ML 2ML 5000 | $264.4K | 7 | 3.5% |
| 8 | FARBE FIRMA PRIVATE LIMITED | $134.6K | 6 | 1.8% |
| 9 | NEM LABORATORIES PVT LTD BRAND VERZEPAM INJ DIAZEPAM BP 5MG/ML 2MBRAND VERZEPAM INJ DIAZEPAM BP 5MG/ML,2MDIAZI DIAZEPAM INJECTION 5MG/ML, 2 ML393,600 AMPS | $129.9K | 6 | 1.7% |
| 10 | SHALINA LABORATORIES PRIVATE LIMITED | $124.6K | 2 | 1.7% |
| 11 | RUSAN PHARMA LIMITED | $121.4K | 1 | 1.6% |
| 12 | PSYCHOTROPICS INDIA LIMITED | $119.4K | 3 | 1.6% |
| 13 | BHARAT PARENTERALS LIMITED | $101.1K | 3 | 1.3% |
| 14 | SAKAR HEALTHCARE LIMITED DIAZI DIAZEPAM INJECTION 5MG/ML, 2 ML393,600 AMPSDIAZEPAM INJECTION BP | $87.9K | 4 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Diazepam exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Mylan Laboratories Limited | Approved | Yes | Yes | Multiple | FDA-approved ANDAs; WHO-GMP certified; EU GMP compliant. |
| Gland Pharma Ltd | Approved | Yes | Yes | Multiple | FDA-approved ANDAs; WHO-GMP certified; EU GMP compliant. |
| Swiss Parenterals Limited | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA or EU GMP listings found. |
| Bharat Parenterals Limited | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA or EU GMP listings found. |
| Ultra Laboratories Pvt Ltd | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA or EU GMP listings found. |
TransData Nexus reviewed the regulatory standing of 5 leading Diazepam exporters from India. 2 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 2 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Diazepam sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for Active Pharmaceutical Ingredients (APIs) production. The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. Its advanced R&D infrastructure and skilled workforce make it a prime location for sourcing high-quality APIs, such as Diazepam.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with companies like Zydus Cadila and Torrent Pharmaceuticals leading the sector. This region's strong regulatory compliance and infrastructure support make it ideal for manufacturing Diazepam formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceuticals. Mumbai, being India's financial capital, offers robust logistics and port facilities, facilitating efficient international distribution. Companies like Cipla, headquartered in Mumbai, leverage this infrastructure to export products like Diazepam to global markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is India's largest pharmaceutical manufacturing hub by volume. The region benefits from tax incentives and government support, attracting numerous pharmaceutical companies. Its strategic location and cost advantages make it a significant player in the production of various pharmaceuticals, including Diazepam.
5Sourcing Recommendations
- Evaluate API Suppliers in Hyderabad: Given Hyderabad's prominence in API production, consider sourcing Diazepam APIs from established manufacturers in this region to ensure quality and compliance.
- Partner with Formulation Experts in Gujarat: Collaborate with companies in the Ahmedabad-Vadodara corridor for the development and manufacturing of Diazepam formulations, leveraging their expertise and regulatory adherence.
- Utilize Mumbai's Export Infrastructure: Leverage the logistical advantages of the Mumbai-Thane-Raigad region for efficient distribution and export of Diazepam products to international markets.
- Consider Cost Benefits in Baddi: Explore manufacturing opportunities in Baddi to take advantage of tax incentives and cost-effective production capabilities for Diazepam.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Diazepam exporters from India
Viatris Inc. (formerly Mylan Laboratories Limited) — Viatris divests non-core businesses for $3.6 billion
In October 2023, Viatris reached agreements to divest nearly all of its over-the-counter (OTC) business, women's healthcare business, and India-based active pharmaceutical ingredients (API) business for approximately $3.6 billion. - IMPACT: This divestiture may lead to a strategic refocus on core pharmaceutical products, potentially affecting Diazepam production and export strategies.
Impact: This divestiture may lead to a strategic refocus on core pharmaceutical products, potentially affecting Diazepam production and export strategies.
Viatris Inc. (formerly Mylan Laboratories Limited) — FDA issues warning letter to Viatris' Indore facility
In December 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter and import alert concerning Viatris' manufacturing facility in Indore, India. The alert affects 11 actively distributed products, which will no longer be accepted into the U.S. until the warning is lifted. - IMPACT: This regulatory action could disrupt Diazepam exports from this facility, potentially impacting supply chains and market availability.
Impact: This regulatory action could disrupt Diazepam exports from this facility, potentially impacting supply chains and market availability.
CSL Limited — CSL completes $11.7 billion acquisition of Vifor Pharma
In August 2022, CSL Limited finalized the acquisition of Vifor Pharma for $11.7 billion, expanding its portfolio in iron deficiency, dialysis, nephrology, and rare disease treatments. - IMPACT: While not directly related to Diazepam, this acquisition may influence market dynamics and competitive strategies among pharmaceutical exporters.
Impact: While not directly related to Diazepam, this acquisition may influence market dynamics and competitive strategies among pharmaceutical exporters.
Common Questions — Diazepam Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which diazepam supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, VENOR PHARMA LIMITED leads with 98 recorded shipments worth $1.4M. MYLAN LABORATORIES LIMITED (28 shipments) and GLAND PHARMA LTD (4 shipments) are also established high-volume exporters.
Q How many diazepam manufacturers are there in India?
India has 75 active diazepam exporters with a combined export market of $7.5M across 534 shipments to 77 countries. The top 5 suppliers hold 56.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for diazepam from India?
Average FOB unit price: $11.12 per unit, ranging from $0.00 to $355.01. Average shipment value: $14.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 75 verified Indian exporters of Diazepam ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 534 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 77 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
534 Verified Shipments
75 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists